Janux Therapeutics Stock Alpha and Beta Analysis
| JANX Stock | USD 36.37 0.80 2.15% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Janux Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Janux Therapeutics over a specified time horizon. Remember, high Janux Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Janux Therapeutics' market risk premium analysis include:
Beta 2.34 | Alpha (0.37) | Risk 7.83 | Sharpe Ratio (0.03) | Expected Return (0.20) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Janux |
Janux Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Janux Therapeutics market risk premium is the additional return an investor will receive from holding Janux Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Janux Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Janux Therapeutics' performance over market.| α | -0.37 | β | 2.34 |
Janux Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Janux Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Janux Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Janux Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Janux Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Janux Therapeutics shares will generate the highest return on investment. By understating and applying Janux Therapeutics stock market price indicators, traders can identify Janux Therapeutics position entry and exit signals to maximize returns.
Janux Therapeutics Return and Market Media
The median price of Janux Therapeutics for the period between Mon, Nov 18, 2024 and Sun, Feb 16, 2025 is 48.96 with a coefficient of variation of 16.47. The daily time series for the period is distributed with a sample standard deviation of 8.19, arithmetic mean of 49.7, and mean deviation of 6.93. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Janux Therapeutics CEO sells 1 million in stock | 12/04/2024 |
2 | Acquisition by Meyer Andrew Hollman of 9880 shares of Janux Therapeutics at 20.24 subject to Rule 16b-3 | 12/19/2024 |
3 | Disposition of 25000 shares by David Campbell of Janux Therapeutics at 56.1922 subject to Rule 16b-3 | 12/24/2024 |
4 | Insider Trading | 12/31/2024 |
5 | Acquisition by Meyer Andrew Hollman of 63000 shares of Janux Therapeutics at 53.24 subject to Rule 16b-3 | 01/02/2025 |
6 | Disposition of 5768 shares by Meyer Andrew Hollman of Janux Therapeutics at 54.5111 subject to Rule 16b-3 | 01/14/2025 |
7 | Janux Therapeutics Shares Down 3.5 percent - Time to Sell - MarketBeat | 01/15/2025 |
8 | Disposition of 100 shares by Meyer Andrew Hollman of Janux Therapeutics at 43.6 subject to Rule 16b-3 | 02/03/2025 |
9 | Insider Sell Alert Andrew Meyer Sells Shares of Janux Therapeutics Inc | 02/06/2025 |
10 | Disposition of 40803 shares by Avalon Ventures Xi, L.p. of Janux Therapeutics at 47.77 subject to Rule 16b-3 | 02/07/2025 |
11 | Janux Therapeutics, Inc. Shares Purchased by Lester Murray Antman dba SimplyRich | 02/12/2025 |
About Janux Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Janux or other stocks. Alpha measures the amount that position in Janux Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 0.71 | 0.56 | 0.5 | 0.53 | Revenue Per Share | 0.21 | 0.18 | 0.17 | 0.13 |
Janux Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Janux Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Janux Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Janux Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Janux Therapeutics. Please utilize our Beneish M Score to check the likelihood of Janux Therapeutics' management manipulating its earnings.
| 8th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Janux Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.